Home | Welcome to Contract Pharma   
Last Updated Friday, August 22 2014
Print

Financial Report: Sanofi



Published February 7, 2013
Related Searches: Vaccine
Sanofi 

4Q Revenues: $11.3 billion (+3%)

4Q Earnings: $578.8 million (earnings were $1.9 billion in 4Q11)

FY Revenues: $46.2 billion (+7%)

FY Earnings: $6.8 billion (-12%)

Comments: Pharmaceutical sales were $9.3 billion in the quarter, down 5% due to generic competition and EU austerity measures. Sales lost due to generic competition on main legacy products were $659.4 million, primarily due to declining sales of Eloxatin (-80%), Lovenox (-13%) and Aprovel (-34%). Plavix sales were down 69% to $732.1 million. Diabetes sales were $2.0 billion in the quarter (+21%), with Lantus sales up 23% to $1.8 billion. Vaccine sales were $1.3 billion (+21%) driven by flu vaccines including Vaxigrip and Fluzone (+55%) and Meningitis/Pneumonia vaccines, including Menactra (+82%). New Genzyme sales were $635.6 million (+22%). Consumer Health Care sales were $967.3 million (+11%). Results in comments section represented at CER.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On